{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:22Z","timestamp":1792785022326,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515110402"],"award-info":[{"award-number":["2021A1515110402"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515110402"],"award-info":[{"award-number":["2021A1515110402"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515110402"],"award-info":[{"award-number":["2021A1515110402"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515110402"],"award-info":[{"award-number":["2021A1515110402"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515110402"],"award-info":[{"award-number":["2021A1515110402"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenzhen Excellent Science and technology innovation personnel training project","award":["RCJ20200714114557005"],"award-info":[{"award-number":["RCJ20200714114557005"]}]},{"name":"Shenzhen Excellent Science and technology innovation personnel training project","award":["RCJ20200714114557005"],"award-info":[{"award-number":["RCJ20200714114557005"]}]},{"name":"Shenzhen Excellent Science and technology innovation personnel training project","award":["RCJ20200714114557005"],"award-info":[{"award-number":["RCJ20200714114557005"]}]},{"name":"Shenzhen Excellent Science and technology innovation personnel training project","award":["RCJ20200714114557005"],"award-info":[{"award-number":["RCJ20200714114557005"]}]},{"name":"Shenzhen Excellent Science and technology innovation personnel training project","award":["RCJ20200714114557005"],"award-info":[{"award-number":["RCJ20200714114557005"]}]},{"name":"Shenzhen engineering research center of multi-modal Fusion Medical Intelligent Diagnosis Technology","award":["XMHT20220104016"],"award-info":[{"award-number":["XMHT20220104016"]}]},{"name":"Shenzhen engineering research center of multi-modal Fusion Medical Intelligent Diagnosis Technology","award":["XMHT20220104016"],"award-info":[{"award-number":["XMHT20220104016"]}]},{"name":"Shenzhen engineering research center of multi-modal Fusion Medical Intelligent Diagnosis Technology","award":["XMHT20220104016"],"award-info":[{"award-number":["XMHT20220104016"]}]},{"name":"Shenzhen engineering research center of multi-modal Fusion Medical Intelligent Diagnosis Technology","award":["XMHT20220104016"],"award-info":[{"award-number":["XMHT20220104016"]}]},{"name":"Shenzhen engineering research center of multi-modal Fusion Medical Intelligent Diagnosis Technology","award":["XMHT20220104016"],"award-info":[{"award-number":["XMHT20220104016"]}]},{"name":"Shenzhen Science and Technology Program Basic Research Project","award":["JCYJ20220818100015031"],"award-info":[{"award-number":["JCYJ20220818100015031"]}]},{"name":"Shenzhen Science and Technology Program Basic Research Project","award":["JCYJ20220818100015031"],"award-info":[{"award-number":["JCYJ20220818100015031"]}]},{"name":"Shenzhen Science and Technology Program Basic Research Project","award":["JCYJ20220818100015031"],"award-info":[{"award-number":["JCYJ20220818100015031"]}]},{"name":"Shenzhen Science and Technology Program Basic Research Project","award":["JCYJ20220818100015031"],"award-info":[{"award-number":["JCYJ20220818100015031"]}]},{"name":"Shenzhen Science and Technology Program Basic Research Project","award":["JCYJ20220818100015031"],"award-info":[{"award-number":["JCYJ20220818100015031"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102736"],"award-info":[{"award-number":["82102736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102736"],"award-info":[{"award-number":["82102736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102736"],"award-info":[{"award-number":["82102736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102736"],"award-info":[{"award-number":["82102736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102736"],"award-info":[{"award-number":["82102736"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenzhen Science and Technology Program","award":["RCBS20210609103054027"],"award-info":[{"award-number":["RCBS20210609103054027"]}]},{"name":"Shenzhen Science and Technology Program","award":["RCBS20210609103054027"],"award-info":[{"award-number":["RCBS20210609103054027"]}]},{"name":"Shenzhen Science and Technology Program","award":["RCBS20210609103054027"],"award-info":[{"award-number":["RCBS20210609103054027"]}]},{"name":"Shenzhen Science and Technology Program","award":["RCBS20210609103054027"],"award-info":[{"award-number":["RCBS20210609103054027"]}]},{"name":"Shenzhen Science and Technology Program","award":["RCBS20210609103054027"],"award-info":[{"award-number":["RCBS20210609103054027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) are effective agents for tumor immunotherapy. However, their clinical effectiveness is unsatisfactory due to off-target effects and a suppressive immune microenvironment. This study developed a nanodrug delivery system for bladder cancer (BCa) using PCL-MPEG and PCL-PEG-CHO to synthesize internal hydrophobic and external hydrophilic micelles (PP) that encapsulated water-insoluble astragaloside IV (PPA). The aldehyde group on the surface of PPA reacted with the amino group of aPD-L1, allowing the decoration of this antibody on the surface of the micelles. The resultingPPA@aPD-L1effectively piggybacked astragaloside IV and aPD-L1 antibody. These findings suggest that PPA@aPD-L1 is relatively stable in circulation and efficiently binds to BCa cells with the aid of aPD-L1. Additionally, this strategy prolongs the drug\u2019s retention time in tumors. Compared to PBS, PP, and PPA with PPA\u2009+\u2009aPD-L1 groups, PPA@aPD-L1significantly prolonged the survival of mice with BCa and reduced tumor volume. Mechanistic studies showed that PPA inhibited the NF-\u03baB and STAT3 signaling pathways in tumor cells. Additionally, PPA@aPD-L1increased IFN-\u03b3 and decreased IL-10 expression in bladder tumors, affecting the number and type of intratumorally infiltrating T cells. Our study presents a simple and effective drug delivery system that combines herbal monomers with ICIs. It has demonstrated a potent ability to suppress tumor growth and holds potential for future applications.<\/jats:p>","DOI":"10.1038\/s41598-024-66010-3","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T15:21:40Z","timestamp":1722439300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Chenfan","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"8","key":"66010_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. & Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol. .Immunol 17(8), 807\u2013821 (2020).","journal-title":"Cell Mol. .Immunol"},{"key":"66010_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216038","volume":"555","author":"Z Wang","year":"2023","unstructured":"Wang, Z., Wang, Y., Gao, P. & Ding, J. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett. 555, 216038 (2023).","journal-title":"Cancer Lett."},{"issue":"8","key":"66010_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103666","volume":"28","author":"Z Peng","year":"2023","unstructured":"Peng, Z., Li, M., Li, H. & Gao, Q. PD-1\/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities. Drug Discov. Today 28(8), 103666 (2023).","journal-title":"Drug Discov. Today"},{"key":"66010_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901772","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Current advances in PD-1\/PD-L1 blockade in recurrent epithelial ovarian cancer. Front. Immunol. 13, 901772 (2022).","journal-title":"Front. Immunol."},{"issue":"4","key":"66010_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37(4), 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"issue":"1","key":"66010_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118(1), 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"66010_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108707","volume":"226","author":"J Majidpoor","year":"2021","unstructured":"Majidpoor, J. & Mortezaee, K. The efficacy of PD-1\/PD-L1 blockade in cold cancers and future perspectives. Clin. Immunol. 226, 108707 (2021).","journal-title":"Clin. Immunol."},{"issue":"4","key":"66010_CR8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/gutjnl-2020-321031","volume":"71","author":"J Huang","year":"2022","unstructured":"Huang, J. et al. Ginseng polysaccharides alter the gut microbiota and kynurenine\/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1\/programmed cell death ligand 1 (anti-PD-1\/PD-L1) immunotherapy. Gut 71(4), 734\u2013745 (2022).","journal-title":"Gut"},{"issue":"1","key":"66010_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/med.21530","volume":"39","author":"J Yang","year":"2019","unstructured":"Yang, J. & Hu, L. Immunomodulators targeting the PD-1\/PD-L1 protein-protein interaction: From antibodies to small molecules. Med. Res. Rev. 39(1), 265\u2013301 (2019).","journal-title":"Med. Res. Rev."},{"key":"66010_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/bs.apha.2019.08.002","volume":"87","author":"J Zhang","year":"2020","unstructured":"Zhang, J., Wu, C., Gao, L., Du, G. & Qin, X. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Adv. Pharmacol. 87, 89\u2013112 (2020).","journal-title":"Adv. Pharmacol."},{"key":"66010_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115625","volume":"167","author":"T Ziyang","year":"2023","unstructured":"Ziyang, T., Xirong, H., Chongming, A. & Tingxin, L. The potential molecular pathways of Astragaloside-IV in colorectal cancer: A systematic review. Biomed. Pharmacother. 167, 115625 (2023).","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"66010_CR12","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1139\/bcb-2020-0026","volume":"99","author":"Y He","year":"2021","unstructured":"He, Y. et al. Astragaloside IV enhanced carboplatin sensitivity in prostate cancer by suppressing AKT\/NF-\u03baB signaling pathway. Biochem. Cell Biol. 99(2), 214\u2013222 (2021).","journal-title":"Biochem. Cell Biol."},{"issue":"3","key":"66010_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2021.4846","volume":"47","author":"T Chen","year":"2021","unstructured":"Chen, T., Yang, P. & Jia, Y. Molecular mechanisms of astragaloside-IV in cancer therapy (Review). Int. J. Mol. Med. 47(3), 1\u20131 (2021).","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"66010_CR14","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1080\/10717544.2022.2094498","volume":"29","author":"B Li","year":"2022","unstructured":"Li, B. et al. Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: A review. Drug Deliv. 29(1), 2130\u20132161 (2022).","journal-title":"Drug Deliv."},{"issue":"1","key":"66010_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","volume":"65","author":"H Maeda","year":"2013","unstructured":"Maeda, H., Nakamura, H. & Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65(1), 71\u201379 (2013).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"66010_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114614","volume":"191","author":"R Sun","year":"2022","unstructured":"Sun, R. et al. The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives. Adv. Drug Deliv. Rev. 191, 114614 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"66010_CR17","doi-asserted-by":"publisher","first-page":"10082","DOI":"10.3390\/ijms241210082","volume":"24","author":"J Kim","year":"2023","unstructured":"Kim, J., Cho, H., Lim, D. K., Joo, M. K. & Kim, K. Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors. Int. J. Mol. Sci. 24(12), 10082 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"66010_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","volume":"20","author":"RH Fang","year":"2023","unstructured":"Fang, R. H., Gao, W. & Zhang, L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat. Rev. Clin. Oncol. 20(1), 33\u201348 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"66010_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20(2), 101\u2013124 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"23","key":"66010_CR20","doi-asserted-by":"publisher","first-page":"10475","DOI":"10.1021\/acs.jmedchem.9b00511","volume":"62","author":"A Ahmad","year":"2019","unstructured":"Ahmad, A., Khan, F., Mishra, R. K. & Khan, R. Precision cancer nanotherapy: Evolving role of multifunctional nanoparticles for cancer active targeting. J. Med. Chem. 62(23), 10475\u201310496 (2019).","journal-title":"J. Med. Chem."},{"issue":"1","key":"66010_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-021-01155-6","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi, M. et al. Combine and conquer: Manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J. Hematol. Oncol. 14(1), 146 (2021).","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"66010_CR22","doi-asserted-by":"publisher","first-page":"e003464","DOI":"10.1136\/jitc-2021-003464","volume":"9","author":"SH Chen","year":"2021","unstructured":"Chen, S. H. et al. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. J. Immunother. Cancer 9(10), e003464 (2021).","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"66010_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","volume":"70","author":"LB Kennedy","year":"2020","unstructured":"Kennedy, L. B. & Salama, A. K. S. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 70(2), 86\u2013104 (2020).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"66010_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18(3), 175\u2013196 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"66010_CR25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/mabi.201400376","volume":"15","author":"Y Shen","year":"2015","unstructured":"Shen, Y. et al. Effect of amphiphilic PCL-PEG nano-micelles on HepG2 cell migration. Macromol. Biosci. 15(3), 372\u2013384 (2015).","journal-title":"Macromol. Biosci."},{"key":"66010_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","volume":"332","author":"B Ghosh","year":"2021","unstructured":"Ghosh, B. & Biswas, S. Polymeric micelles in cancer therapy: State of the art. J. Control Release 332, 127\u2013147 (2021).","journal-title":"J. Control Release"},{"key":"66010_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2017.05.028","volume":"260","author":"P Grossen","year":"2017","unstructured":"Grossen, P., Witzigmann, D., Sieber, S. & Huwyler, J. PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application. J. Control Release 260, 46\u201360 (2017).","journal-title":"J. Control Release"},{"key":"66010_CR28","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2147\/IJN.S349516","volume":"17","author":"Z Hou","year":"2022","unstructured":"Hou, Z. et al. Poly(\u03b5-Caprolactone)-Methoxypolyethylene glycol (PCL-MPEG)-based micelles for drug-delivery: The effect of PCL chain length on blood components, phagocytosis, and biodistribution. Int. J. Nanomed. 17, 1613\u20131632 (2022).","journal-title":"Int. J. Nanomed."},{"issue":"16","key":"66010_CR29","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.3390\/molecules28166118","volume":"28","author":"Y Liang","year":"2023","unstructured":"Liang, Y. et al. Pharmacological effects of astragaloside IV: A review. Molecules 28(16), 6118 (2023).","journal-title":"Molecules"},{"issue":"10","key":"66010_CR30","doi-asserted-by":"publisher","first-page":"734.e1","DOI":"10.1016\/j.urolonc.2021.06.001","volume":"39","author":"GB Schulz","year":"2021","unstructured":"Schulz, G. B. et al. PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?. Urol. Oncol. 39(10), 734.e1-734.e10 (2021).","journal-title":"Urol. Oncol."},{"issue":"22","key":"66010_CR31","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.3390\/cancers13225841","volume":"13","author":"A Vikerfors","year":"2021","unstructured":"Vikerfors, A., Davidsson, S., Frey, J., Jerlstr\u00f6m, T. & Carlsson, J. Soluble PD-L1 in serum and urine in urinary bladder cancer patients. Cancers (Basel) 13(22), 5841 (2021).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"66010_CR32","doi-asserted-by":"publisher","first-page":"14244","DOI":"10.1038\/s41598-021-93754-z","volume":"11","author":"G Tosev","year":"2021","unstructured":"Tosev, G. et al. Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. Sci. Rep. 11(1), 14244 (2021).","journal-title":"Sci. Rep."},{"issue":"6","key":"66010_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/his.13710","volume":"73","author":"JJ de Jong","year":"2018","unstructured":"de Jong, J. J., Stoop, H., Nieboer, D., Boormans, J. L. & van Leenders, G. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Histopathology 73(6), 983\u2013989 (2018).","journal-title":"Histopathology"},{"issue":"2","key":"66010_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jconrel.2004.07.007","volume":"99","author":"ID Rosca","year":"2004","unstructured":"Rosca, I. D., Watari, F. & Uo, M. Microparticle formation and its mechanism in single and double emulsion solvent evaporation. J. Control Release 99(2), 271\u2013280 (2004).","journal-title":"J. Control Release"},{"issue":"3","key":"66010_CR35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/j.1552-4604.1994.tb03993.x","volume":"34","author":"GK Szabo","year":"1994","unstructured":"Szabo, G. K., Browne, H. K., Ajami, A. & Josephs, E. G. Alternatives to least squares linear regression analysis for computation of standard curves for quantitation by high performance liquid chromatography: applications to clinical pharmacology. J. Clin. Pharmacol. 34(3), 242\u2013249 (1994).","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"66010_CR36","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1038\/s41598-021-86860-5","volume":"11","author":"A Elamir","year":"2021","unstructured":"Elamir, A. et al. Ultrasound-triggered herceptin liposomes for breast cancer therapy. Sci. Rep. 11(1), 7545 (2021).","journal-title":"Sci. Rep."},{"key":"66010_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119420","volume":"222","author":"J Peng","year":"2019","unstructured":"Peng, J. et al. Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer. Biomaterials 222, 119420 (2019).","journal-title":"Biomaterials"},{"issue":"28","key":"66010_CR38","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1002\/adma.201103192","volume":"24","author":"SM Loverde","year":"2012","unstructured":"Loverde, S. M., Klein, M. L. & Discher, D. E. Nanoparticle shape improves delivery: Rational coarse grain molecular dynamics (rCG-MD) of taxol in worm-like PEG-PCL micelles. Adv. Mater. 24(28), 3823\u20133830 (2012).","journal-title":"Adv. Mater."},{"issue":"11","key":"66010_CR39","doi-asserted-by":"publisher","first-page":"1700324","DOI":"10.1002\/advs.201700324","volume":"4","author":"X Xin","year":"2017","unstructured":"Xin, X. et al. Rod-shaped active drug particles enable efficient and safe gene delivery. Adv. Sci. (Weinh) 4(11), 1700324 (2017).","journal-title":"Adv. Sci. (Weinh)"},{"issue":"33","key":"66010_CR40","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.0801763105","volume":"105","author":"SE Gratton","year":"2008","unstructured":"Gratton, S. E. et al. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 105(33), 11613\u201311618 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"66010_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201906832","volume":"16","author":"Z Su","year":"2020","unstructured":"Su, Z. et al. Codelivery of Anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and Ph dual-sensitive micelles for enhanced tumor chemoimmunotherapy. Small 16(7), e1906832 (2020).","journal-title":"Small"},{"issue":"5","key":"66010_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201806202","volume":"31","author":"T Lang","year":"2019","unstructured":"Lang, T. et al. Cocktail strategy based on spatio-temporally controlled nano device improves therapy of breast cancer. Adv. Mater. 31(5), e1806202 (2019).","journal-title":"Adv. Mater."},{"key":"66010_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122067","volume":"296","author":"M Lin","year":"2023","unstructured":"Lin, M. et al. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer. Biomaterials 296, 122067 (2023).","journal-title":"Biomaterials"},{"issue":"1","key":"66010_CR44","doi-asserted-by":"publisher","first-page":"e20190418","DOI":"10.1084\/jem.20190418","volume":"217","author":"M Saraiva","year":"2020","unstructured":"Saraiva, M., Vieira, P. & O\u2019Garra, A. Biology and therapeutic potential of interleukin. J. Exp. Med. 217(1), e20190418 (2020).","journal-title":"J. Exp. Med."},{"key":"66010_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cytogfr.2016.02.003","volume":"30","author":"J Geginat","year":"2016","unstructured":"Geginat, J. et al. The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. Cytokine Growth Factor Rev. 30, 87\u201393 (2016).","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1\u20132","key":"66010_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1023\/A:1015944709177","volume":"234\u2013235","author":"PA Ward","year":"2002","unstructured":"Ward, P. A. & Lentsch, A. B. Endogenous regulation of the acute inflammatory response. Mol. Cell Biochem. 234\u2013235(1\u20132), 225\u2013228 (2002).","journal-title":"Mol. Cell Biochem."},{"key":"66010_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-\u03b3 in tumor progression and regression: A review. Biomark. Res. 8, 49 (2020).","journal-title":"Biomark. Res."},{"issue":"1","key":"66010_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat, M. et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur. Urol. 84(1), 49\u201364 (2023).","journal-title":"Eur. Urol."},{"issue":"1","key":"66010_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal, R., Valderrama, B. P. & Bellmunt, J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat. Rev. Clin. Oncol. 21(1), 8\u201327 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"66010_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely, M. D., Zhang, T. & Chen, L. Resistance mechanisms to anti-PD cancer immunotherapy. Ann. Rev. Immunol. 40, 45\u201374 (2022).","journal-title":"Ann. Rev. Immunol."},{"key":"66010_CR51","doi-asserted-by":"publisher","first-page":"1131635","DOI":"10.3389\/fphar.2023.1131635","volume":"14","author":"R Li","year":"2023","unstructured":"Li, R. et al. Fufang shenhua tablet, astragali radix and its active component astragaloside IV: Research progress on anti-inflammatory and immunomodulatory mechanisms in the kidney. Front. Pharmacol. 14, 1131635 (2023).","journal-title":"Front. Pharmacol."},{"issue":"4","key":"66010_CR52","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF03190631","volume":"30","author":"Y Du","year":"2005","unstructured":"Du, Y., Zhang, Q., Chen, G. G., Wei, P. & Tu, C. Y. Pharmacokinetics of Astragaloside IV in rats by liquid chromatography coupled with tandem mass spectrometry. Eur. J. Drug Metab. Pharmacokinet. 30(4), 269\u2013273 (2005).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66010-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66010-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66010-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T15:31:45Z","timestamp":1722439905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66010-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66010"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-66010-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17704"}}